NASDAQ:OMCL - Omnicell Technologies Stock Price, Price Target & More

$43.12 -0.78 (-1.78 %)
(As of 04/20/2018 12:30 PM ET)
Previous Close$43.90
Today's Range$42.95 - $43.75
52-Week Range$38.00 - $55.40
Volume73,290 shs
Average Volume273,656 shs
Market Capitalization$1.73 billion
P/E Ratio239.44
Dividend YieldN/A
Beta0.74

About Omnicell Technologies (NASDAQ:OMCL)

Omnicell Technologies logoOmnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Debt-to-Equity Ratio0.38%
Current Ratio1.73%
Quick Ratio1.28%

Price-To-Earnings

Trailing P/E Ratio239.44
Forward P/E Ratio56.00
P/E Growth3.67

Sales & Book Value

Annual Sales$716.16 million
Price / Sales2.34
Cash Flow$1.5428 per share
Price / Cash27.95
Book Value$13.64 per share
Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins2.88%
Return on Equity1.54%
Return on Assets0.77%

Miscellaneous

Employees2,350
Outstanding Shares38,860,000

How to Become a New Pot Stock Millionaire

Omnicell Technologies (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell Technologies' stock symbol?

Omnicell Technologies trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell Technologies' earnings last quarter?

Omnicell Technologies (NASDAQ:OMCL) posted its quarterly earnings results on Thursday, February, 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million for the quarter, compared to analyst estimates of $205.50 million. Omnicell Technologies had a return on equity of 1.54% and a net margin of 2.88%. The firm's revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. View Omnicell Technologies' Earnings History.

When is Omnicell Technologies' next earnings date?

Omnicell Technologies is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Omnicell Technologies.

What guidance has Omnicell Technologies issued on next quarter's earnings?

Omnicell Technologies issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.85-2.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98. The company issued revenue guidance of $780-800 million, compared to the consensus revenue estimate of $809.67 million.Omnicell Technologies also updated its Q1 guidance to $0.22-0.28 EPS.

What price target have analysts set for OMCL?

7 equities research analysts have issued twelve-month price objectives for Omnicell Technologies' stock. Their forecasts range from $44.00 to $67.00. On average, they anticipate Omnicell Technologies' stock price to reach $56.1429 in the next twelve months. View Analyst Ratings for Omnicell Technologies.

What are Wall Street analysts saying about Omnicell Technologies stock?

Here are some recent quotes from research analysts about Omnicell Technologies stock:
  • 1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
  • 2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)

Who are some of Omnicell Technologies' key competitors?

Who are Omnicell Technologies' key executives?

Omnicell Technologies' management team includes the folowing people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Chief Exec. Officer and Pres (Age 61)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 45)
  • Mr. J. Christopher Drew, Pres of North American Automation and Analytics (Age 52)
  • Mr. Robin G. Seim, Pres of Global Automation and Medication Adherence (Age 58)

Has Omnicell Technologies been receiving favorable news coverage?

Media stories about OMCL stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell Technologies earned a media sentiment score of 0.04 on Accern's scale. They also gave media headlines about the company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Omnicell Technologies?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell Technologies' stock price today?

One share of OMCL stock can currently be purchased for approximately $43.17.

How big of a company is Omnicell Technologies?

Omnicell Technologies has a market capitalization of $1.73 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell Technologies employs 2,350 workers across the globe.

How can I contact Omnicell Technologies?

Omnicell Technologies' mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell Technologies (OMCL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Omnicell Technologies and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Omnicell Technologies (NASDAQ:OMCL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Omnicell Technologies in the last 12 months. Their average twelve-month price target is $56.1429, suggesting that the stock has a possible upside of 30.20%. The high price target for OMCL is $67.00 and the low price target for OMCL is $44.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.862.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.1429$56.1429$55.1429$51.8571
Price Target Upside: 30.20% upside24.07% upside7.81% upside1.32% downside

Omnicell Technologies (NASDAQ:OMCL) Consensus Price Target History

Price Target History for Omnicell Technologies (NASDAQ:OMCL)

Omnicell Technologies (NASDAQ:OMCL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2018Cantor FitzgeraldReiterated RatingBuy$63.00MediumView Rating Details
2/2/2018Piper JaffrayBoost Price TargetNeutral -> Neutral$38.00 -> $44.00HighView Rating Details
2/2/2018Craig HallumDowngradeBuy -> HoldHighView Rating Details
1/29/2018OppenheimerReiterated RatingBuy$55.00MediumView Rating Details
9/5/2017BenchmarkBoost Price TargetBuy -> Buy$55.00 -> $67.00MediumView Rating Details
7/28/2017Dougherty & CoBoost Price TargetBuy$45.00 -> $49.00HighView Rating Details
4/26/2017CIBCBoost Price TargetOutperform$43.00 -> $53.00LowView Rating Details
9/8/2016SidotiDowngradeBuy -> Neutral$43.00N/AView Rating Details
7/29/2016FBR & CoBoost Price TargetOutperform$40.00 -> $41.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Omnicell Technologies (NASDAQ:OMCL) Earnings History and Estimates Chart

Earnings by Quarter for Omnicell Technologies (NASDAQ:OMCL)

Omnicell Technologies (NASDAQ:OMCL) Earnings Estimates

Current Year EPS Consensus Estimate: $0.77 EPS
Next Year EPS Consensus Estimate: $1.15 EPS

Omnicell Technologies (NASDAQ OMCL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.37N/AView Earnings Details
2/1/2018Q4 2017$0.52$0.54$205.50 million$198.26 millionViewListenView Earnings Details
10/26/2017Q3 2017$0.42$0.42$192.45 million$186.78 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.02$0.02$174.08 million$180.90 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.30)$0.06$152.63 million$150.90 millionViewListenView Earnings Details
2/15/2017Q4 2016$0.41$0.37$179.28 million$171.97 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.40$179.75 million$179.40 millionViewListenView Earnings Details
7/28/2016Q216$0.32$0.38$170.89 million$175.60 millionViewListenView Earnings Details
4/28/2016Q116$0.26$0.35$167.18 million$171.00 millionViewListenView Earnings Details
2/4/2016Q415$0.39$0.40$126.89 million$130.30 millionViewListenView Earnings Details
10/29/2015Q315$0.36$0.36$128.50 million$125.20 millionViewListenView Earnings Details
7/30/2015Q215$0.32$0.28$121.35 million$112.80 millionViewListenView Earnings Details
4/30/2015Q115$0.23$0.29$112.00 million$16.20 millionViewN/AView Earnings Details
2/3/2015Q414$0.33$0.39$114.65 million$121.50 millionViewListenView Earnings Details
10/30/2014Q314$0.31$0.30$106.10 million$112.50 millionViewListenView Earnings Details
7/31/2014Q214$0.29$0.30$103.23 million$105.10 millionViewListenView Earnings Details
5/1/2014Q114$0.24$0.26$97.49 million$101.80 millionViewListenView Earnings Details
2/4/2014Q413$0.28$0.29$101.13 million$105.80 millionViewListenView Earnings Details
10/31/2013Q313$0.28$0.31$94.96 million$94.03 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.25$0.27$92.42 million$93.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.19$0.21$87.20 million$87.11 millionViewN/AView Earnings Details
1/31/2013Q4 2012$0.25$0.25$87.31 million$90.16 millionViewN/AView Earnings Details
10/25/2012$0.22$0.29ViewN/AView Earnings Details
8/1/2012$0.18$0.20ViewN/AView Earnings Details
5/2/2012$0.13$0.13ViewN/AView Earnings Details
1/26/2012$0.16$0.19ViewN/AView Earnings Details
10/27/2011$0.16$0.16ViewN/AView Earnings Details
7/28/2011$0.13$0.15ViewN/AView Earnings Details
5/2/2011$0.10$0.11ViewN/AView Earnings Details
1/27/2011$0.12$0.11ViewN/AView Earnings Details
10/27/2010Q3 2010$0.02$0.02ViewN/AView Earnings Details
7/22/2010Q2 2010$0.04$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.02$0.03ViewN/AView Earnings Details
1/28/2010Q4 2009$0.03$0.02ViewN/AView Earnings Details
10/22/2009Q3 2009$0.02$0.03ViewN/AView Earnings Details
7/23/2009Q2 2009$0.01$0.03ViewN/AView Earnings Details
4/30/2009Q1 2009($0.02)($0.01)ViewN/AView Earnings Details
1/29/2009Q4 2008$0.07$0.10ViewN/AView Earnings Details
10/23/2008Q3 2008$0.09$0.09ViewN/AView Earnings Details
7/21/2008Q2 2008$0.08$0.09ViewN/AView Earnings Details
4/21/2008Q1 2008$0.11$0.11ViewN/AView Earnings Details
1/31/2008Q4 2007$0.20$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Omnicell Technologies (NASDAQ:OMCL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Omnicell Technologies (NASDAQ OMCL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.71%
Insider Trading History for Omnicell Technologies (NASDAQ:OMCL)
Institutional Ownership by Quarter for Omnicell Technologies (NASDAQ:OMCL)

Omnicell Technologies (NASDAQ OMCL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Dan S JohnstonEVPSell11,284$44.95$507,215.8046,430View SEC Filing  
4/12/2018Peter J KuipersInsiderSell724$46.00$33,304.0056,970View SEC Filing  
3/15/2018Gary S PetersmeyerDirectorSell575$44.43$25,547.25View SEC Filing  
3/6/2018Randall A LippsChairmanSell8,186$44.21$361,903.06224,206View SEC Filing  
12/18/2017Peter J KuipersCFOSell1,926$51.69$99,554.9440,544View SEC Filing  
11/17/2017Dan S JohnstonEVPSell14,613$47.81$698,647.5343,621View SEC Filing  
11/17/2017Peter J KuipersVPSell4,724$47.74$225,523.7640,544View SEC Filing  
11/6/2017Jorge R TaborgaVPSell6,295$48.69$306,503.5550,013View SEC Filing  
10/2/2017Peter J KuipersVPSell3,532$50.96$179,990.7240,714View SEC Filing  
9/15/2017Robin Gene SeimEVPSell9,780$48.97$478,926.6055,896View SEC Filing  
9/5/2017Gary S. PetersmeyerDirectorSell1,000$51.73$51,730.00View SEC Filing  
9/1/2017Randall A. LippsChairmanSell10,625$52.00$552,500.00View SEC Filing  
8/18/2017Dan S JohnstonEVPSell16,400$48.86$801,304.0051,621View SEC Filing  
8/15/2017Robin Gene SeimEVPSell15,109$50.86$768,443.7458,144View SEC Filing  
8/9/2017Peter J KuipersVPSell18,054$50.31$908,296.7444,236View SEC Filing  
8/8/2017J Christopher DrewVPSell11,375$51.16$581,945.00139,201View SEC Filing  
8/7/2017Jorge R TaborgaVPSell20,719$50.98$1,056,254.6253,270View SEC Filing  
8/1/2017Randall A LippsChairmanSell40,000$49.76$1,990,400.00196,551View SEC Filing  
7/28/2017Randall A LippsChairmanSell37,500$46.00$1,725,000.00196,551View SEC Filing  
6/19/2017Randall A LippsChairmanSell31,527$42.87$1,351,562.49196,551View SEC Filing  
6/5/2017Randall A LippsChairmanSell9,900$43.00$425,700.00208,982View SEC Filing  
5/26/2017James T JudsonDirectorSell12,148$41.50$504,142.0019,130View SEC Filing  
5/25/2017Gary S PetersmeyerDirectorSell2,200$41.41$91,102.0021,075View SEC Filing  
5/19/2017Dan S JohnstonEVPSell16,400$40.67$666,988.0061,696View SEC Filing  
5/9/2017J Christopher DrewVPSell10,625$40.97$435,306.25152,057View SEC Filing  
4/25/2017Randall A LippsChairmanSell18,200$41.00$746,200.00208,982View SEC Filing  
3/10/2017Gary S PetersmeyerDirectorSell2,658$37.45$99,542.1020,085View SEC Filing  
2/21/2017Sara J WhiteDirectorSell3,443$38.06$131,040.5843,214View SEC Filing  
11/18/2016Dan S JohnstonEVPSell8,850$33.65$297,802.5058,877View SEC Filing  
11/18/2016Jorge R TaborgaVPSell2,068$33.66$69,608.8847,223View SEC Filing  
11/8/2016J Christopher DrewVPSell20,000$31.95$639,000.00139,844View SEC Filing  
9/12/2016Gary S PetersmeyerDirectorSell2,000$37.98$75,960.0017,987View SEC Filing  
9/8/2016Gary S PetersmeyerDirectorSell2,400$39.39$94,536.0017,987View SEC Filing  
9/6/2016Gary S PetersmeyerDirectorSell2,000$39.02$78,040.0019,987View SEC Filing  
9/2/2016Gary S PetersmeyerDirectorSell3,000$38.52$115,560.0019,987View SEC Filing  
8/19/2016Dan S JohnstonEVPSell8,850$36.93$326,830.5064,877View SEC Filing  
8/19/2016Jorge R TaborgaVPSell1,778$36.92$65,643.7649,073View SEC Filing  
8/11/2016Randall A LippsChairmanSell37,425$37.37$1,398,572.25192,325View SEC Filing  
8/9/2016J Christopher DrewVPSell15,000$37.89$568,350.00139,844View SEC Filing  
8/9/2016James T JudsonDirectorSell6,250$37.98$237,375.0015,300View SEC Filing  
8/4/2016Gary S PetersmeyerDirectorSell8,750$37.84$331,100.0019,987View SEC Filing  
7/29/2016Jorge R TaborgaVPSell10,023$40.00$400,920.0049,073View SEC Filing  
7/6/2016Robin Gene SeimEVPSell5,302$34.75$184,244.5055,420View SEC Filing  
7/1/2016Robin Gene SeimEVPSell3,645$35.00$127,575.0055,420View SEC Filing  
6/6/2016Jorge R TaborgaVPSell25,979$33.00$857,307.0050,734View SEC Filing  
5/24/2016Gary S PetersmeyerDirectorSell6,250$31.22$195,125.0015,557View SEC Filing  
5/20/2016Dan S JohnstonEVPSell8,850$30.73$271,960.5073,105View SEC Filing  
5/20/2016Jorge R TaborgaVPSell1,933$30.73$59,401.0952,667View SEC Filing  
5/10/2016J Christopher DrewVPSell15,000$31.63$474,450.00144,573View SEC Filing  
5/5/2016Sara J WhiteDirectorSell2,000$31.76$63,520.0040,433View SEC Filing  
4/29/2016Robin Gene SeimEVPSell6,407$31.00$198,617.0059,619View SEC Filing  
4/26/2016Jorge R TaborgaVPSell23,827$30.00$714,810.0052,667View SEC Filing  
4/26/2016Robin Gene SeimEVPSell767$30.00$23,010.0060,386View SEC Filing  
2/19/2016Dan S JohnstonEVPSell8,850$27.41$242,578.5079,716View SEC Filing  
2/19/2016Jorge R TaborgaVPSell1,685$27.42$46,202.7054,806View SEC Filing  
2/11/2016Randall A. LippsCEOSell40,000$27.81$1,112,400.00204,705View SEC Filing  
2/9/2016J Christopher DrewVPSell15,000$27.57$413,550.00145,355View SEC Filing  
12/18/2015Nhat H. NgoVPSell4,069$28.71$116,820.9923,431View SEC Filing  
11/17/2015Dan S. JohnstonVPSell2,500$28.00$70,000.0066,393View SEC Filing  
11/10/2015J Christopher DrewVPSell25,000$26.79$669,750.00137,180View SEC Filing  
11/9/2015Dan S. JohnstonVPSell2,700$27.29$73,683.0066,393View SEC Filing  
10/13/2015Gary S. PetersmeyerDirectorSell670$31.66$21,212.2015,557View SEC Filing  
8/13/2015Robin Gene SeimCFOSell23,946$35.63$853,195.98View SEC Filing  
7/1/2015Robin Gene SeimCFOSell19,582$37.84$740,982.88View SEC Filing  
6/17/2015Nhat H NgoVPSell4,067$38.78$157,718.26View SEC Filing  
6/2/2015James T JudsonDirectorSell8,032$36.83$295,818.56View SEC Filing  
6/2/2015Nhat H NgoVPSell6,375$36.80$234,600.00View SEC Filing  
5/26/2015Sara J WhiteDirectorSell4,000$36.25$145,000.00View SEC Filing  
5/7/2015Dan S JohnstonVPSell7,715$34.25$264,238.75View SEC Filing  
2/12/2015J Christopher DrewVPSell25,000$34.62$865,500.00View SEC Filing  
2/6/2015Dan S JohnstonVPSell6,552$33.29$218,116.08View SEC Filing  
2/2/2015James T JudsonDirectorSell5,000$31.61$158,050.00View SEC Filing  
1/13/2015Gary S PetersmeyerDirectorSell670$31.31$20,977.70View SEC Filing  
1/2/2015James T JudsonDirectorSell5,000$32.36$161,800.00View SEC Filing  
1/2/2015Robin Gene SeimCFOSell1,948$32.36$63,037.28View SEC Filing  
12/17/2014Marga Ortigas-WedekindVPSell4,080$32.20$131,376.00View SEC Filing  
12/15/2014Gary S PetersmeyerDirectorSell670$33.25$22,277.50View SEC Filing  
12/8/2014Nhat H NgoVPSell1,754$32.89$57,689.06View SEC Filing  
12/1/2014James T JudsonDirectorSell5,000$31.94$159,700.00View SEC Filing  
11/12/2014Randy D LindholmDirectorSell5,000$31.72$158,600.00View SEC Filing  
11/11/2014J Christopher DrewVPSell37,500$31.86$1,194,750.00View SEC Filing  
11/7/2014Dan S JohnstonVPSell27,625$31.74$876,817.50View SEC Filing  
11/3/2014James T JudsonDirectorSell5,000$32.27$161,350.00View SEC Filing  
10/3/2014Nhat H NgoVPSell2,275$28.00$63,700.00View SEC Filing  
10/1/2014James T JudsonDirectorSell5,000$27.02$135,100.00View SEC Filing  
9/15/2014Jorge R TaborgaVPSell944$26.37$24,893.28View SEC Filing  
9/15/2014Robin Gene SeimCFOSell9,347$26.32$246,013.04View SEC Filing  
9/2/2014James T JudsonDirectorSell5,000$28.18$140,900.00View SEC Filing  
9/2/2014Robin Gene SeimCFOSell27,500$28.19$775,225.00View SEC Filing  
8/26/2014Dan S JohnstonVPSell6,250$28.00$175,000.00View SEC Filing  
8/26/2014James T JudsonDirectorSell9,913$27.91$276,671.83View SEC Filing  
7/9/2014Robin Gene SeimCFOSell2,442$28.21$68,888.82View SEC Filing  
7/1/2014James T JudsonDirectorSell5,000$29.28$146,400.00View SEC Filing  
6/26/2014Marga Ortigas-WedekindVPSell2,961$28.17$83,411.37View SEC Filing  
6/25/2014Nhat H NgoVPSell2,274$28.00$63,672.00View SEC Filing  
6/17/2014Nhat H NgoVPSell1,420$27.70$39,334.00View SEC Filing  
6/10/2014Nhat H NgoVPSell1,964$26.38$51,810.32View SEC Filing  
6/2/2014Gary S PetersmeyerDirectorSell5,000$26.45$132,250.00View SEC Filing  
5/21/2014Gary PetersmeyerDirectorSell2,000$26.51$53,020.0017,088View SEC Filing  
5/13/2014J Christopher DrewVPSell37,500$26.08$978,000.00151,448View SEC Filing  
5/7/2014Dan JohnstonVPSell4,000$25.25$101,000.0075,558View SEC Filing  
5/1/2014James JudsonDirectorSell5,000$26.24$131,200.0017,945View SEC Filing  
4/8/2014Nhat NgoVPSell1,002$27.40$27,454.8052,896View SEC Filing  
3/18/2014Marga Ortigas-WedekindVPSell5,880$30.00$176,400.0053,445View SEC Filing  
3/18/2014Randall LippsCEOSell124,910$29.89$3,733,559.90220,997View SEC Filing  
12/18/2013Nhat NgoVPSell1,462$24.43$35,716.6645,585View SEC Filing  
12/18/2013Randall LippsCEOSell64,739$24.30$1,573,157.70186,048View SEC Filing  
12/3/2013Dan JohnstonVPSell73,419$23.24$1,706,257.5674,885View SEC Filing  
11/11/2013Randy LindholmDirectorSell3,587$23.00$82,501.0026,917View SEC Filing  
11/7/2013Dan JohnstonVPSell8,000$22.99$183,920.0074,885View SEC Filing  
10/23/2013Robin Gene SeimCFOSell7,664$24.50$187,768.00View SEC Filing  
10/21/2013Robin Gene SeimCFOSell9,349$23.76$222,132.24View SEC Filing  
10/1/2013James T JudsonDirectorSell5,000$23.66$118,300.00View SEC Filing  
9/24/2013Randall LippsCEOSell68,204$25.00$1,705,100.00202,362View SEC Filing  
9/23/2013Marga Ortigas-WedekindVPSell4,000$25.00$100,000.0080,903View SEC Filing  
9/23/2013Randall LippsCEOSell5,083$25.00$127,075.00202,362View SEC Filing  
9/20/2013Robin Gene SeimCFOSell27,500$24.35$669,625.0069,700View SEC Filing  
9/18/2013Randall LippsCEOSell64,453$23.67$1,525,602.51202,362View SEC Filing  
9/4/2013Nhat H NgoVPSell7,362$24.00$176,688.00View SEC Filing  
9/3/2013James JudsonDirectorSell5,000$22.77$113,850.0017,945View SEC Filing  
8/20/2013James JudsonDirectorSell11,724$22.74$266,603.7617,945View SEC Filing  
8/13/2013J Christopher DrewVPSell20,000$22.83$456,600.00131,221View SEC Filing  
8/12/2013Donald WegmillerDirectorSell34,976$22.87$799,901.128,002View SEC Filing  
8/7/2013Dan JohnstonVPSell8,000$22.92$183,360.0074,885View SEC Filing  
8/6/2013Randall LippsCEOSell5,321$23.00$122,383.00211,905View SEC Filing  
8/2/2013Randall A LippsCEOSell25,000$22.50$562,500.00View SEC Filing  
8/1/2013James JudsonDirectorSell5,000$21.00$105,000.0029,669View SEC Filing  
7/19/2013Nhat H NgoVPSell41,875$21.00$879,375.00View SEC Filing  
7/19/2013Randall A LippsCEOSell5,080$21.00$106,680.00View SEC Filing  
7/1/2013James T JudsonDirectorSell5,000$20.46$102,300.00View SEC Filing  
7/1/2013Robin Gene SeimCFOSell13,032$20.42$266,113.44View SEC Filing  
6/28/2013Marga Ortigas-WedekindVPSell4,545$20.00$90,900.00View SEC Filing  
6/28/2013Randall A LippsCEOSell25,000$20.00$500,000.00View SEC Filing  
6/21/2013Nhat H NgoVPSell3,459$19.01$65,755.59View SEC Filing  
6/18/2013Randall A LippsCEOSell66,378$19.10$1,267,819.80View SEC Filing  
6/10/2013Randy D LindholmDirectorSell23,901$19.14$457,465.14View SEC Filing  
6/4/2013Robin Gene SeimCFOSell25,000$18.72$468,000.00View SEC Filing  
5/22/2013Gary S PetersmeyerDirectorSell2,750$18.10$49,775.00View SEC Filing  
5/16/2013J Christopher DrewVPSell26,000$18.69$485,940.00View SEC Filing  
5/14/2013J Christopher DrewVPSell26,000$18.45$479,700.00View SEC Filing  
5/10/2013Sara J WhiteDirectorSell7,200$18.50$133,200.00View SEC Filing  
5/7/2013Dan S JohnstonVPSell8,000$18.44$147,520.00View SEC Filing  
12/3/2012Gary S PetersmeyerDirectorSell1,359$15.17$20,616.03View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Omnicell Technologies (NASDAQ OMCL) News Headlines

Source:
DateHeadline
Omnicell Technologies (OMCL) Stock Rating Lowered by BidaskClubOmnicell Technologies (OMCL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 20 at 11:17 AM
Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018
finance.yahoo.com - April 19 at 4:42 PM
Omnicell Technologies (OMCL) Expected to Post Quarterly Sales of $177.37 MillionOmnicell Technologies (OMCL) Expected to Post Quarterly Sales of $177.37 Million
www.americanbankingnews.com - April 19 at 2:12 AM
Omnicell Technologies (OMCL) Expected to Post Earnings of $0.27 Per ShareOmnicell Technologies (OMCL) Expected to Post Earnings of $0.27 Per Share
www.americanbankingnews.com - April 17 at 9:12 PM
Omnicell Technologies (OMCL) EVP Dan S. Johnston Sells 11,284 SharesOmnicell Technologies (OMCL) EVP Dan S. Johnston Sells 11,284 Shares
www.americanbankingnews.com - April 16 at 7:14 PM
Analyzing Omnicell Technologies (OMCL) and Teradata (TDC)Analyzing Omnicell Technologies (OMCL) and Teradata (TDC)
www.americanbankingnews.com - April 15 at 9:09 PM
Omnicell Technologies (OMCL) Receives Average Rating of "Buy" from AnalystsOmnicell Technologies (OMCL) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 11:29 AM
Omnicell Technologies (OMCL) Insider Sells $33,304.00 in StockOmnicell Technologies (OMCL) Insider Sells $33,304.00 in Stock
www.americanbankingnews.com - April 12 at 7:35 PM
Omnicell Technologies (OMCL) versus Dell Technologies (DVMT) Financial ContrastOmnicell Technologies (OMCL) versus Dell Technologies (DVMT) Financial Contrast
www.americanbankingnews.com - April 12 at 1:29 AM
Comparing Omnicell Technologies (OMCL) & NICE Systems (NICE)Comparing Omnicell Technologies (OMCL) & NICE Systems (NICE)
www.americanbankingnews.com - April 11 at 8:45 AM
Omnicells Medication Management Automation Portfolio to Be Featured at the American Organization of Nurse Executives 2018 ConferenceOmnicell's Medication Management Automation Portfolio to Be Featured at the American Organization of Nurse Executives 2018 Conference
finance.yahoo.com - April 10 at 9:49 AM
Head-To-Head Review: Omnicell Technologies (OMCL) & Capcom (CCOEY)Head-To-Head Review: Omnicell Technologies (OMCL) & Capcom (CCOEY)
www.americanbankingnews.com - April 10 at 1:31 AM
Omnicell Appoints Scott Seidelmann as Chief Commercial OfficerOmnicell Appoints Scott Seidelmann as Chief Commercial Officer
finance.yahoo.com - April 9 at 9:38 AM
Omnicell Technologies (OMCL) Upgraded by BidaskClub to "Hold"Omnicell Technologies (OMCL) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 7 at 9:29 AM
Craig Hallum Reaffirms "Buy" Rating for Omnicell Technologies (OMCL)Craig Hallum Reaffirms "Buy" Rating for Omnicell Technologies (OMCL)
www.americanbankingnews.com - April 4 at 1:21 PM
Omnicell Technologies (OMCL) Earns Buy Rating from Cantor FitzgeraldOmnicell Technologies (OMCL) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 3 at 5:16 PM
Omnicell Technologies (OMCL) Expected to Announce Quarterly Sales of $177.37 MillionOmnicell Technologies (OMCL) Expected to Announce Quarterly Sales of $177.37 Million
www.americanbankingnews.com - April 2 at 2:08 AM
$0.27 Earnings Per Share Expected for Omnicell Technologies (OMCL) This Quarter$0.27 Earnings Per Share Expected for Omnicell Technologies (OMCL) This Quarter
www.americanbankingnews.com - March 31 at 9:08 PM
Reviewing Omnicell Technologies (OMCL) & Cancer Genetics (CGIX)Reviewing Omnicell Technologies (OMCL) & Cancer Genetics (CGIX)
www.americanbankingnews.com - March 27 at 3:20 PM
Mercyhealth Adopts Omnicells XR2 Automated Central Pharmacy System to Enhance Patient SafetyMercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety
finance.yahoo.com - March 27 at 9:49 AM
Omnicell (OMCL) Upgraded at BidaskClubOmnicell (OMCL) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Head to Head Contrast: Omnicell (OMCL) and The Ensign Group (ENSG)Head to Head Contrast: Omnicell (OMCL) and The Ensign Group (ENSG)
www.americanbankingnews.com - March 23 at 1:32 AM
Omnicell To Present At Needham & Companys 17th Annual Healthcare ConferenceOmnicell To Present At Needham & Company's 17th Annual Healthcare Conference
finance.yahoo.com - March 22 at 4:28 PM
Omnicell, Inc. (OMCL) Receives Consensus Recommendation of "Hold" from AnalystsOmnicell, Inc. (OMCL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 11:27 AM
Omnicell to Showcase Industry-Leading Medication Management Automation ...Omnicell to Showcase Industry-Leading Medication Management Automation ...
www.prnewswire.com - March 20 at 4:23 PM
Omnicell to Showcase Industry-Leading Medication Management Automation Platform and Solutions at the European Association of Hospital Pharmacists CongressOmnicell to Showcase Industry-Leading Medication Management Automation Platform and Solutions at the European Association of Hospital Pharmacists Congress
finance.yahoo.com - March 20 at 9:37 AM
Omnicell, Inc. (OMCL) Director Gary S. Petersmeyer Sells 575 SharesOmnicell, Inc. (OMCL) Director Gary S. Petersmeyer Sells 575 Shares
www.americanbankingnews.com - March 16 at 8:52 PM
 Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $177.37 Million Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $177.37 Million
www.americanbankingnews.com - March 16 at 3:27 AM
Infirmary Health Adopts Omnicells Sterile Compounding Solutions and ServicesInfirmary Health Adopts Omnicell's Sterile Compounding Solutions and Services
finance.yahoo.com - March 14 at 10:24 AM
Omnicell, Inc. (OMCL) Chairman Sells $361,903.06 in StockOmnicell, Inc. (OMCL) Chairman Sells $361,903.06 in Stock
www.americanbankingnews.com - March 8 at 12:31 AM
Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 5 at 9:37 AM
Martingale Asset Management L P Reduces Stake in Omnicell, Inc. (OMCL)Martingale Asset Management L P Reduces Stake in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 4 at 12:50 PM
Arizona State Retirement System Has $3.09 Million Position in Omnicell, Inc. (OMCL)Arizona State Retirement System Has $3.09 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 4 at 4:32 AM
Omnicell, Inc. (OMCL) Short Interest Down 32.8% in FebruaryOmnicell, Inc. (OMCL) Short Interest Down 32.8% in February
www.americanbankingnews.com - March 4 at 2:56 AM
Omnicell Opens Center of Excellence in Cranberry Township, Showcasing ...Omnicell Opens Center of Excellence in Cranberry Township, Showcasing ...
www.prnewswire.com - March 3 at 5:13 PM
Kennedy Capital Management Inc. Has $22.58 Million Position in Omnicell, Inc. (OMCL)Kennedy Capital Management Inc. Has $22.58 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 2 at 5:27 PM
Omnicell, Inc. (OMCL) Holdings Reduced by Snyder Capital Management L POmnicell, Inc. (OMCL) Holdings Reduced by Snyder Capital Management L P
www.americanbankingnews.com - March 2 at 1:50 PM
B. Braun To Showcase Latest Information Technology Capabilities at HIMSS18B. Braun To Showcase Latest Information Technology Capabilities at HIMSS18
feeds.benzinga.com - March 1 at 2:43 PM
King Luther Capital Management Corp Has $3.46 Million Position in Omnicell, Inc. (OMCL)King Luther Capital Management Corp Has $3.46 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 1 at 11:42 AM
Omnicell Opens Center of Excellence in Cranberry Township, Showcasing Innovation and Industry-Leading Medication Management PlatformOmnicell Opens Center of Excellence in Cranberry Township, Showcasing Innovation and Industry-Leading Medication Management Platform
finance.yahoo.com - March 1 at 9:07 AM
Omnicell Inc (OMCL) Files 10-K for the Fiscal Year Ended on December 31, 2017Omnicell Inc (OMCL) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 5:05 PM
Head-To-Head Analysis: NantHealth (NH) & Omnicell (OMCL)Head-To-Head Analysis: NantHealth (NH) & Omnicell (OMCL)
www.americanbankingnews.com - February 27 at 10:10 AM
Omnicells Industry-Leading Medication Management Automation Platform and Solutions to Be Featured at HIMSS18Omnicell's Industry-Leading Medication Management Automation Platform and Solutions to Be Featured at HIMSS18
finance.yahoo.com - February 27 at 9:25 AM
Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $177.37 MillionOmnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $177.37 Million
www.americanbankingnews.com - February 27 at 7:06 AM
Omnicell, Inc. (OMCL) Shares Sold by Champlain Investment Partners LLCOmnicell, Inc. (OMCL) Shares Sold by Champlain Investment Partners LLC
www.americanbankingnews.com - February 27 at 5:38 AM
796,115 Shares in Omnicell, Inc. (OMCL) Acquired by Carillon Tower Advisers Inc.796,115 Shares in Omnicell, Inc. (OMCL) Acquired by Carillon Tower Advisers Inc.
www.americanbankingnews.com - February 27 at 5:32 AM
Omnicell, Inc. (OMCL) Stake Lifted by Monroe Bank & Trust MIOmnicell, Inc. (OMCL) Stake Lifted by Monroe Bank & Trust MI
www.americanbankingnews.com - February 26 at 3:50 PM
$0.26 EPS Expected for Omnicell, Inc. (OMCL) This Quarter$0.26 EPS Expected for Omnicell, Inc. (OMCL) This Quarter
www.americanbankingnews.com - February 25 at 7:08 PM
Omnicell, Inc. (OMCL) Given Consensus Rating of "Hold" by AnalystsOmnicell, Inc. (OMCL) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 24 at 2:50 PM
Commit To Purchase Omnicell At $35, Earn 6.6% Annualized Using OptionsCommit To Purchase Omnicell At $35, Earn 6.6% Annualized Using Options
www.nasdaq.com - February 23 at 4:58 PM

SEC Filings

Omnicell Technologies (NASDAQ:OMCL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Omnicell Technologies (NASDAQ:OMCL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Omnicell Technologies (NASDAQ OMCL) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.